title: Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
abstract: BACKGROUND
  The human monoclonal antibody SK-1 recognizes a glycoprotein expressed on the majority of colon cancer tissues. In the current study, we evaluated the safety, toxicity and preliminary efficacy of escalating dosages of SK-1 in patients with advanced colon cancer.
  
  
  METHODS
  SK-1 was administered intravenously at 2, 4 or 10 mg three times to three groups of patients with recurrent colon cancer. The clinical outcome and the induction of serum anti-idiotypic antibody (Ab2) were assessed periodically.
  
  
  RESULTS
  The mean rate of serum CEA level increase declined significantly during the eight weeks following the treatment. In four patients, serum titer of anti-idiotypic IgG antibodies to SK-1 (Ab2) continued to increase following the treatment.
  
  
  CONCLUSIONS
  HuMAb SK-1 was well-tolerated and can be safely administered. It was suggested that SK-1 natural antibody not only possessed direct cytostatic activity against colon carcinoma, but may also have induced carcinoma-related, anti-idiotypic antibody responses.
authors: Department of Surgery I, Chiba University School of Medicine, Chiba City, 260-8670 Japan. k-koda@umin.ac.jp
authors: K
authors: K
authors: Koda
authors: M C
authors: MC
authors: Glassy
authors: M E
authors: ME
authors: McKnight
authors: J
authors: J
authors: Yasutomi
authors: N
authors: N
authors: Saito
authors: M
authors: M
authors: Dan
authors: N
authors: N
authors: Nakajima
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007106:Immune Sera; D007116:Immunization, Passive; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D008297:Male; D051379:Mice; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000628:therapy; D009363:Neoplasm Proteins / Q000097:blood / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000628:therapy; D011817:Rabbits; D012449:Safety; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins; D007106:Immune Sera; D007140:Immunoglobulin Fab Fragments; D009363:Neoplasm Proteins